The global amyloidosis treatment market size was estimated to be USD 5.81 billion in 2023 and is expected to reach USD 12.83 billion by 2034 with a CAGR of 7.46% during the forecast period 2024-2034. The market will grow as a result of the increasing incidence of amyloidosis, technological advancements in diagnostics, increased focus on rare diseases, improved healthcare infrastructure, increased awareness and support programs, and strategic alliances and collaborations.
Ongoing research and development of novel therapies, such as monoclonal antibodies, RNA-based treatments, and gene-editing tools, are transforming the landscape of amyloidosis treatment by providing more effective and targeted options. In December 2023, Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced that the U.S. Food and Drug Administration (FDA) has approved WAINUA™ (eplontersen), developed in collaboration with AstraZeneca, for treating the polyneuropathy associated with hereditary transthyretin-mediated amyloidosis in adults, commonly known as hATTR-PN or ATTRv-PN. Notably, WAINUA is the only approved treatment for ATTRv-PN that can be self-administered using an auto-injector, offering greater patient convenience.
By treatment, the chemotherapy segment accounted for the highest revenue-grossing segment in the global amyloidosis treatment market in 2023 owing to the widespread use of chemotherapy as a first-line treatment option for systemic amyloidosis, particularly in combination with stem cell transplants and other therapies. For instance, in January 2024, Ultromics - a patient outcomes-driven, artificial intelligence (AI) driven health technology firm with roots at the University of Oxford, UK - entered into a partnership with Pfizer to facilitate the FDA's clearance and validation of Ultromics' AI-based cardiac amyloidosis detection tool. Additionally, the transplantation segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing success rates of stem cell transplants and the rising adoption of liver and kidney transplants for amyloidosis patients with organ failure.
By drug class, the transthyretin transport inhibitors segment accounted for the highest revenue-grossing segment in the global amyloidosis treatment market in 2023 owing to the growing use of drugs like Tafamidis, which stabilize transthyretin and help slow the progression of transthyretin amyloidosis, especially in patients with familial amyloid polyneuropathy. For instance, In October 2023, Alnylam Pharmaceuticals, Inc. announced the publication of data from the APOLLO-B Phase 3 study of patisiran in patients with cardiomyopathy of ATTR amyloidosis. When compared to a placebo, the study found that after 12 months, patisiran maintained functionality capacity, health condition, and quality of life. Additionally, the immunomodulatory drugs segment is predicted to grow at the fastest CAGR during the forecast period due to the increasing research on therapies like lenalidomide and pomalidomide, which have shown promising results in managing AL amyloidosis by modulating the immune system and improving patient outcomes.
By end-user, the hospitals and clinics segment accounted for the highest revenue-grossing segment in the global amyloidosis treatment market in 2023 due to the availability of advanced diagnostic and therapeutic facilities in hospitals, as well as the need for specialized care for amyloidosis patients, particularly those undergoing chemotherapy and transplantation. For instance, Ionis Pharmaceuticals, Inc. reported today that it will present new subgroup findings at the 2024 International Symposium on Amyloidosis (ISA) in Rochester, Minnesota, May 26-30, from Ionis and AstraZeneca's Phase 3 NEURO-TTRansform study of WAINUATM (eplontersen). In December 2023, the U.S., FDA in the United States approved WAINUA for the treatment of adult patients with polyneuropathy due to hereditary transthyretin-mediated amyloidosis, also known as hATTR-PN or ATTRv-PN. Additionally, the home care settings segment is predicted to grow at the fastest CAGR during the forecast period due to the rising demand for at-home treatment options for amyloidosis patients, including the administration of medications, monitoring, and symptom management, which improve patient convenience and reduce hospital visits.
North American region is anticipated for the highest revenue share during the forecast period owing to the well-established healthcare infrastructure, high prevalence of amyloidosis, strong presence of key market players, and early adoption of advanced treatments such as chemotherapy and novel drug therapies. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the improving healthcare systems, increasing awareness and diagnosis of amyloidosis, growing patient population, and rising investments in research and development for rare diseases. For instance, BioMap announced today, October 2023, a ground-breaking strategic partnership with Sanofi to jointly create state-of-the-art AI modules for biotherapeutic drug development using BioMap's AI platform.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Ongoing research and development of novel therapies, such as monoclonal antibodies, RNA-based treatments, and gene-editing tools, are transforming the landscape of amyloidosis treatment by providing more effective and targeted options. In December 2023, Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced that the U.S. Food and Drug Administration (FDA) has approved WAINUA™ (eplontersen), developed in collaboration with AstraZeneca, for treating the polyneuropathy associated with hereditary transthyretin-mediated amyloidosis in adults, commonly known as hATTR-PN or ATTRv-PN. Notably, WAINUA is the only approved treatment for ATTRv-PN that can be self-administered using an auto-injector, offering greater patient convenience.
By treatment, the chemotherapy segment accounted for the highest revenue-grossing segment in the global amyloidosis treatment market in 2023 owing to the widespread use of chemotherapy as a first-line treatment option for systemic amyloidosis, particularly in combination with stem cell transplants and other therapies. For instance, in January 2024, Ultromics - a patient outcomes-driven, artificial intelligence (AI) driven health technology firm with roots at the University of Oxford, UK - entered into a partnership with Pfizer to facilitate the FDA's clearance and validation of Ultromics' AI-based cardiac amyloidosis detection tool. Additionally, the transplantation segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing success rates of stem cell transplants and the rising adoption of liver and kidney transplants for amyloidosis patients with organ failure.
By drug class, the transthyretin transport inhibitors segment accounted for the highest revenue-grossing segment in the global amyloidosis treatment market in 2023 owing to the growing use of drugs like Tafamidis, which stabilize transthyretin and help slow the progression of transthyretin amyloidosis, especially in patients with familial amyloid polyneuropathy. For instance, In October 2023, Alnylam Pharmaceuticals, Inc. announced the publication of data from the APOLLO-B Phase 3 study of patisiran in patients with cardiomyopathy of ATTR amyloidosis. When compared to a placebo, the study found that after 12 months, patisiran maintained functionality capacity, health condition, and quality of life. Additionally, the immunomodulatory drugs segment is predicted to grow at the fastest CAGR during the forecast period due to the increasing research on therapies like lenalidomide and pomalidomide, which have shown promising results in managing AL amyloidosis by modulating the immune system and improving patient outcomes.
By end-user, the hospitals and clinics segment accounted for the highest revenue-grossing segment in the global amyloidosis treatment market in 2023 due to the availability of advanced diagnostic and therapeutic facilities in hospitals, as well as the need for specialized care for amyloidosis patients, particularly those undergoing chemotherapy and transplantation. For instance, Ionis Pharmaceuticals, Inc. reported today that it will present new subgroup findings at the 2024 International Symposium on Amyloidosis (ISA) in Rochester, Minnesota, May 26-30, from Ionis and AstraZeneca's Phase 3 NEURO-TTRansform study of WAINUATM (eplontersen). In December 2023, the U.S., FDA in the United States approved WAINUA for the treatment of adult patients with polyneuropathy due to hereditary transthyretin-mediated amyloidosis, also known as hATTR-PN or ATTRv-PN. Additionally, the home care settings segment is predicted to grow at the fastest CAGR during the forecast period due to the rising demand for at-home treatment options for amyloidosis patients, including the administration of medications, monitoring, and symptom management, which improve patient convenience and reduce hospital visits.
North American region is anticipated for the highest revenue share during the forecast period owing to the well-established healthcare infrastructure, high prevalence of amyloidosis, strong presence of key market players, and early adoption of advanced treatments such as chemotherapy and novel drug therapies. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the improving healthcare systems, increasing awareness and diagnosis of amyloidosis, growing patient population, and rising investments in research and development for rare diseases. For instance, BioMap announced today, October 2023, a ground-breaking strategic partnership with Sanofi to jointly create state-of-the-art AI modules for biotherapeutic drug development using BioMap's AI platform.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Treatment, Drug Class, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement.
Segmentation: Amyloidosis Treatment Market Report 2023 - 2034
Amyloidosis Treatment Market Analysis & Forecast by Treatment 2023 - 2034 (Revenue USD Bn)
- Chemotherapy
- Immunosuppressive Drugs
- Transplantation
- Supportive Care
- Surgery
- Others
Amyloidosis Treatment Market Analysis & Forecast by Drug Class 2023 - 2034 (Revenue USD Bn)
- Transthyretin Transport Inhibitor
- Immunomodulatory Drugs
- Monoclonal Antibodies
- Proteasome Inhibitors
- Others
Amyloidosis Treatment Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Bn)
- Hospitals & Clinics
- Ambulatory Surgical Centers
- Home Care Settings
- Others
Amyloidosis Treatment Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Amyloidosis Treatment Market: Treatment Estimates & Trend Analysis
8. Amyloidosis Treatment Market: Drug Class Estimates & Trend Analysis
9. Amyloidosis Treatment Market: End-User Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Amyloidosis Treatment Market
12. Europe Global Amyloidosis Treatment Market
13. Asia Pacific Global Amyloidosis Treatment Market
14. Latin America Global Amyloidosis Treatment Market
15. MEA Global Amyloidosis Treatment Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Alnylam Pharmaceuticals Inc.
- Celgene Corporation (a subsidiary of Bristol-Myers Squibb)
- Prothena Corporation plc
- Eisai Co. Ltd.
- Novartis AG
- Amgen Inc.
- Pfizer Inc.
- Ionis Pharmaceuticals Inc.
- Takeda Pharmaceutical Company Limited
- Bristol-Myers Squibb Company
- Sanofi S.A.
- Boehringer Ingelheim GmbH
- AstraZeneca plc
- GSK (GlaxoSmithKline plc)
- Horizon Therapeutics plc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | December 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 5.81 Billion |
| Forecasted Market Value ( USD | $ 12.83 Billion |
| Compound Annual Growth Rate | 7.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
